Tambo Y, Sone T, Nishi K, Shibata K, et al. Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score >/=50 %: A multicenter observational study. Lung Cancer 2025;201:108422.
PMID: 39952082